AnaptysBio (AN6) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AN6 Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

AnaptysBio

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AN6 Stock 12 Month Forecast

Average Price Target

€69.91

▲(47.25% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for AnaptysBio in the last 3 months. The average price target is €69.91 with a high forecast of €82.34 and a low forecast of €60.67. The average price target represents a 47.25% change from the last price of €47.48.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"€10","83":"€83","28.25":"€28.3","46.5":"€46.5","64.75":"€64.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":82.3364126,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€82.34</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69.91372578666666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€69.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60.6689356,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€60.67</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,28.25,46.5,64.75,83],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.67,48.490493276923075,51.310986553846156,54.13147983076923,56.95197310769231,59.772466384615385,62.59295966153846,65.41345293846155,68.23394621538462,71.0544394923077,73.87493276923077,76.69542604615384,79.51591932307693,{"y":82.3364126,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.67,47.53490198358975,49.39980396717949,51.26470595076923,53.12960793435897,54.99450991794872,56.85941190153846,58.724313885128204,60.58921586871794,62.45411785230769,64.31901983589744,66.18392181948718,68.04882380307691,{"y":69.91372578666666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.67,46.82376427692308,47.977528553846156,49.13129283076923,50.28505710769231,51.43882138461539,52.592585661538465,53.746349938461535,54.90011421538462,56.05387849230769,57.20764276923077,58.36140704615384,59.51517132307692,{"y":60.6689356,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.829,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.219,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.743,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.613,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.222,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.049,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.788,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.398,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.572,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.08,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.68,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.74,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.67,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€82.34

Average Price Target€69.91

Lowest Price Target€60.67

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joseph Pantginis

H.C. Wainwright

€82.34

Buy

73.41%

Upside

Reiterated

08/12/26

Analysts Offer Insights on Healthcare Companies: Vor Biopharma (NASDAQ: VOR), AnaptysBio (NASDAQ: ANAB) and Erasca (NASDAQ: ERAS)

Etzer Darout

Barclays

€65

Buy

36.90%

Upside

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: Mettler-Toledo (NYSE: MTD), AnaptysBio (NASDAQ: ANAB) and Alnylam Pharma (NASDAQ: ALNY)

Yasmeen Rahimi

Piper Sandler

€80.6

Buy

69.76%

Upside

Reiterated

07/21/26

Joseph Thome

TD Cowen

€65

Buy

36.90%

Upside

Reiterated

07/13/26

TD Cowen Remains a Buy on AnaptysBio (ANAB)

Michael Yee

UBS

€65.87

Buy

38.73%

Upside

Reiterated

06/30/26

Analysts Are Bullish on Top Healthcare Stocks: MindWalk Holdings (HYFT), AnaptysBio (ANAB)

David Risinger

Leerink Partners

―

Buy

―

Reiterated

05/27/26

Analysts Offer Insights on Healthcare Companies: AnaptysBio (NASDAQ: ANAB), GeoVax Labs (NASDAQ: GOVX) and Vir Biotechnology (NASDAQ: VIR)

Anupam Rama

J.P. Morgan

€59.8→€60.67

Buy

27.78%

Upside

Reiterated

05/22/26

J.P. Morgan Sticks to Its Buy Rating for AnaptysBio (ANAB)

David Nierengarten

Wedbush

€52→€65

Buy

36.90%

Upside

Reiterated

03/31/26

Wedbush Remains a Buy on AnaptysBio (ANAB)

Joon Lee

Truist Financial

€31.2→€43.33

Hold

-8.73%

Downside

Reiterated

03/09/26

Truist Financial Keeps Their Hold Rating on AnaptysBio (ANAB)

Alex Thompson CFA

Stifel Nicolaus

€48.54→€73.67

Buy

55.16%

Upside

Reiterated

03/05/26

Analysts Are Bullish on These Healthcare Stocks: Veeva Systems (VEEV), Apellis Pharmaceuticals (APLS)

Yatin Suneja

Guggenheim

€121.34

Buy

155.56%

Upside

Reiterated

03/04/26

Guggenheim Reaffirms Their Buy Rating on AnaptysBio (ANAB)

Derek Archila

Wells Fargo

€70.2

Buy

47.86%

Upside

Reiterated

12/16/25

AnaptysBio (ANAB) Receives a Buy from Wells Fargo

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joseph Pantginis

H.C. Wainwright

€82.34

Buy

73.41%

Upside

Reiterated

08/12/26

Analysts Offer Insights on Healthcare Companies: Vor Biopharma (NASDAQ: VOR), AnaptysBio (NASDAQ: ANAB) and Erasca (NASDAQ: ERAS)

Etzer Darout

Barclays

€65

Buy

36.90%

Upside

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: Mettler-Toledo (NYSE: MTD), AnaptysBio (NASDAQ: ANAB) and Alnylam Pharma (NASDAQ: ALNY)

Yasmeen Rahimi

Piper Sandler

€80.6

Buy

69.76%

Upside

Reiterated

07/21/26

Joseph Thome

TD Cowen

€65

Buy

36.90%

Upside

Reiterated

07/13/26

TD Cowen Remains a Buy on AnaptysBio (ANAB)

Michael Yee

UBS

€65.87

Buy

38.73%

Upside

Reiterated

06/30/26

Analysts Are Bullish on Top Healthcare Stocks: MindWalk Holdings (HYFT), AnaptysBio (ANAB)

David Risinger

Leerink Partners

―

Buy

―

Reiterated

05/27/26

Analysts Offer Insights on Healthcare Companies: AnaptysBio (NASDAQ: ANAB), GeoVax Labs (NASDAQ: GOVX) and Vir Biotechnology (NASDAQ: VIR)

Anupam Rama

J.P. Morgan

€59.8→€60.67

Buy

27.78%

Upside

Reiterated

05/22/26

J.P. Morgan Sticks to Its Buy Rating for AnaptysBio (ANAB)

David Nierengarten

Wedbush

€52→€65

Buy

36.90%

Upside

Reiterated

03/31/26

Wedbush Remains a Buy on AnaptysBio (ANAB)

Joon Lee

Truist Financial

€31.2→€43.33

Hold

-8.73%

Downside

Reiterated

03/09/26

Truist Financial Keeps Their Hold Rating on AnaptysBio (ANAB)

Alex Thompson CFA

Stifel Nicolaus

€48.54→€73.67

Buy

55.16%

Upside

Reiterated

03/05/26

Analysts Are Bullish on These Healthcare Stocks: Veeva Systems (VEEV), Apellis Pharmaceuticals (APLS)

Yatin Suneja

Guggenheim

€121.34

Buy

155.56%

Upside

Reiterated

03/04/26

Guggenheim Reaffirms Their Buy Rating on AnaptysBio (ANAB)

Derek Archila

Wells Fargo

€70.2

Buy

47.86%

Upside

Reiterated

12/16/25

AnaptysBio (ANAB) Receives a Buy from Wells Fargo

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

JBIOJade Biosciences

GHRSGH Research

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AnaptysBio

3 Months

Joseph ThomeTD Cowen

Success Rate

13/20 ratings generated profit

Average Return

+15.58%

Copying Joseph Thome's trades and holding each position for 3 Months would result in 65.00% of your transactions generating a profit, with an average return of +15.58% per trade.

1 Year

Anupam RamaJ.P. Morgan

Success Rate

13/17 ratings generated profit

Average Return

+109.69%

Copying Anupam Rama's trades and holding each position for 1 Year would result in 76.47% of your transactions generating a profit, with an average return of +109.69% per trade.

2 Years

Derek ArchilaWells Fargo

Success Rate

13/13 ratings generated profit

Average Return

+260.39%

Copying Derek Archila's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +260.39% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AN6 Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AN6 has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AN6 average Analyst price target in the past 3 months is 69.91.

Each month's total comprises the sum of three months' worth of ratings.

AN6 Financial Forecast

AN6 Earnings Forecast

Currently, no earnings data available.

AN6 Sales Forecast

Currently, no sales data available.

AN6 Stock Forecast FAQ

What is DE:AN6’s average 12-month price target, according to analysts?

Based on analyst ratings, AnaptysBio’s 12-month average price target is 69.91.

What is DE:AN6’s upside potential, based on the analysts’ average price target?

AnaptysBio has 47.25% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AnaptysBio a Buy, Sell or Hold?

AnaptysBio has a consensus rating of Strong Buy, which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is AnaptysBio’s share price target?

The average share price target for AnaptysBio is 69.91. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €82.34 ,and the lowest forecast is €60.67. The average share price target represents 47.25% Increase from the current price of €47.48.

What do analysts say about AnaptysBio?

AnaptysBio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of AnaptysBio?

To buy shares of DE:AN6, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

AnaptysBio (AN6) Stock Forecast & Price Target

AN6 Analyst Ratings

AN6 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AnaptysBio

AN6 Analyst Recommendation Trends

AN6 Financial Forecast

AN6 Earnings Forecast

AN6 Sales Forecast

AN6 Stock Forecast FAQ

Detailed List of Analyst Forecasts